🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Carla I. Falkson

University of Rochester Medicine

ORCID: 0000-0003-2370-6818

Also affiliated with University of Rochester

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.742Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

medRxiv(2023)10.1101/2023.03.06.23286772
Top 27%
0.742DataRank
Top 27%12 citations

Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Papers

Driven by 8 papers — median percentile 73. Top paper: “Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030”.

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

Annals of Oncology(2023)10.1016/j.annonc.2023.08.004
N/A
1.7DataRank · unranked
58 citations

Timothy Blewett, Xun Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1
N/A
1.4DataRank · unranked
43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

medRxiv(2023)10.1101/2023.03.06.23286772
Top 27%
0.742DataRank
Top 27%12 citations

Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2
N/A
0.510DataRank · unranked
29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba612
N/A
0.165DataRank · unranked
2 citations

Alexandra Thomas, Christina Yau, A. Jo Chien, Carla I. Falkson, Erica Stringer-Reasor +15 more

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba520
N/A
0.165DataRank · unranked
2 citations

Kevin Kalinsky, Christina Yau, A. Jo Chien, Judy C. Boughey, Erica Stringer-Reasor +15 more

Streamlining regulatory review in a multicenter platform trial: Opportunity to enhance patient centered care and drive innovation and efficiency.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1572
N/A
0.104DataRank · unranked
1 citations

Teresa Helsten, Brian Moore, Linda Neuhauser, Barbara LeStage, Paolo Castillo +12 more

Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.525
N/A
0DataRank · unranked
0 citations

Lauren Lenz, Elizabeth S. Cogan, Erica L. Mayer, Virginia Kaklamani, Vered Stearns +15 more